WallStreetZenWallStreetZen

NASDAQ: CRVO
Cervomed Inc Stock Forecast, Predictions & Price Target

Analyst price target for CRVO

Based on 1 analyst offering 12 month price targets for Cervomed Inc.
Min Forecast
$65.00+247.78%
Avg Forecast
$65.00+247.78%
Max Forecast
$65.00+247.78%

Should I buy or sell CRVO stock?

Based on 1 analyst offering ratings for Cervomed Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CRVO stock forecasts and price targets.

CRVO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-08

1 of 1

Forecast return on equity

Is CRVO forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.8%

Forecast return on assets

Is CRVO forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CRVO revenue forecast

What is CRVO's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$8.0M+25.7%
Avg 2 year Forecast
$5.9M-7.3%
CRVO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRVO revenue growth forecast

How is CRVO forecast to perform vs Biotechnology companies and vs the US market?
Company
26.77%
Industry
35.34%
Market
10.16%
CRVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRVO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRVO$18.69$65.00+247.78%Strong Buy
CRDF$3.44$10.50+205.23%Strong Buy
SGMT$4.82$32.25+569.09%Strong Buy
VXRT$0.87$2.00+130.95%Strong Buy
XFOR$0.90$3.00+232.23%Buy

Cervomed Stock Forecast FAQ

Is Cervomed Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CRVO) stock is to Strong Buy CRVO stock.

Out of 1 analyst, 1 (100%) are recommending CRVO as a Strong Buy, 0 (0%) are recommending CRVO as a Buy, 0 (0%) are recommending CRVO as a Hold, 0 (0%) are recommending CRVO as a Sell, and 0 (0%) are recommending CRVO as a Strong Sell.

If you're new to stock investing, here's how to buy Cervomed stock.

What is CRVO's revenue growth forecast for 2024-2025?

(NASDAQ: CRVO) Cervomed's forecast annual revenue growth rate of 26.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.34%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Cervomed's revenue in 2024 is $6,364,310.On average, 1 Wall Street analysts forecast CRVO's revenue for 2024 to be $66,029,928, with the lowest CRVO revenue forecast at $66,029,928, and the highest CRVO revenue forecast at $66,029,928.

In 2025, CRVO is forecast to generate $48,697,072 in revenue, with the lowest revenue forecast at $48,697,072 and the highest revenue forecast at $48,697,072.

What is CRVO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CRVO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CRVO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CRVO price target, the average CRVO price target is $65.00, with the highest CRVO stock price forecast at $65.00 and the lowest CRVO stock price forecast at $65.00.

The Wall Street analyst predicted that Cervomed's share price could reach $65.00 by Apr 8, 2025. The average Cervomed stock price prediction forecasts a potential upside of 247.78% from the current CRVO share price of $18.69.

What is CRVO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CRVO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.